About Post-Menopausal Vaginal Atrophy Drugs
Vaginal atrophy also known as atrophic vaginitis is defined as a decrease in the production of estrogen after menopause, leading to thinning, drying, and reduced elasticity of the vaginal tissues. Up to 40% of post-menopausal women have symptoms of atrophic vaginitis. It typically affects women in the age group of 45-55 years. PVA result in symptoms such as itching, burning, dryness, and dyspareunia. Topical preparations such as hormone replacement therapy (HRT) and estrogen creams are used to treat PVA.
Technavio’s analysts forecast the global PVA drugs market to grow at a CAGR of 7.13% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global PVA drugs market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of drugs (creams, tablets, patches, and rings) used to treat PVA.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Post-Menopausal Vaginal Atrophy Drugs Market 2016-2020
Technavio recognizes the following companies as the key players in the Global Post-Menopausal Vaginal Atrophy Drugs Market: Pfizer Inc., Allergan Inc., Shionogi & Co. Ltd., Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd.
Other Prominent Vendors in the market are: Bayer, Bionovo, EndoCeutics, Foamix Pharmaceuticals, Ligand Pharmaceuticals, Pantarhei Bioscience, Pep-Tonic Medical, TherapeuticsMD, and Upsher-Smith Laboratories.
Commenting on the report, an analyst from Technavio’s team said: “Non-estrogenic therapies in PVA treatment are a paradigm shift from systemic estrogen therapies such as creams, patches, and gels. In addition, the launch of late-stage pipeline products is expected to shift the attention from vaginal creams and OTC classes toward vaginal tablets and oral therapies. For instance, the recent launch of two non-estrogenic therapies with improved safety profiles, Osphena by Shionogi and BZA/CE by Bayer, will allow manufacturers to tap a large pool of untreated people. ”
According to the report, the Affordable Care Act has increased the number of insured women and has been a driving factor in the treatment-seeking behavior of people with this condition. The law puts in place comprehensive health insurance reforms that will roll out over four years and beyond. This provides Americans with better health security by putting in place comprehensive health insurance reforms that lower healthcare costs and expand the coverage.
Further, the report states that the market is currently served by generic products due to the patent expiries of branded products such as Premarin, which lost its patent in 2012. The patent of Colpotrophine also expired in 2015. Patent expiries will lead to the entry of generic versions of the particular drugs in the market, resulting in the sales erosion of branded products. This will result in heavy financial loss to the parent drug makers.
Pfizer Inc., Allergan Inc., Shionogi & Co. Ltd., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Bayer, Bionovo, EndoCeutics, Foamix Pharmaceuticals, Ligand Pharmaceuticals, Pantarhei Bioscience, Pep-Tonic Medical, TherapeuticsMD, Upsher-Smith Laboratories.